-+ 0.00%
-+ 0.00%
-+ 0.00%

Cognition Therapeutics Highlights Blood Test Screening Efficiencies in Phase 2 Alzheimer's Trial

PUBT·11/17/2026 11:03:41
Listen to the news
Cognition Therapeutics Highlights Blood Test Screening Efficiencies in Phase 2 Alzheimer's Trial
  • Cognition Therapeutics’ partners will present Phase 2 START screening findings at the CTAD conference in Boston on November 19, 2026.
  • Early p-tau217 blood testing identified ineligible participants before amyloid PET scans, potentially reducing unnecessary imaging, screening visits and trial-site costs.
  • START is evaluating once-daily oral zervimesine against placebo in 545 participants with mild cognitive impairment or early Alzheimer’s disease.
  • Enrollment concluded in the fourth quarter of 2025; top-line results are expected once the last participants complete 18 months of treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170600PRIMZONEFULLFEED9878679) on November 17, 2026, and is solely responsible for the information contained therein.